Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations

Lloyd, Amanda Abramson; Klintmalm, Göran B.; Qin, Haili; Menter, Alan

doi:10.1111/ctr.12490

Cited by 19 publications

(17 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…In a population of SOTRs, Lloyd et al 16 found that 49% of patients with metastatic cutaneous malignancies died from their disease. Yet, 72% of these deceased SOTRs were seen by physicians who seldom referred patients for dermatologic screening 16 . Additionally, Ong et al 25 found that 27% of heart transplant recipients died due to untreated skin cancer within four years of their transplant date.…”

Section: Discussionmentioning

confidence: 99%

“…With only 14% of SOTRs being referred to dermatologists posttransplant, skin cancer severity in SOTRs is underestimated. The primary reason cited for a physician to avoid a dermatology referral was a lack of sufficient medical evidence warranting screening in SOTRs 16 . We conducted this retrospective review in order to update the transplant literature on metastatic cutaneous malignancies in transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

2017

ARC Journal of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

2017

ARC Journal of Dermatology

View full text Add to dashboard Cite

“…A primer prevenció részeként fontos lenne már a transzplantáció előtt a betegek egyéni rizikófaktorainak felmérése, bőrük vizsgálata, figyelmük felhívása és oktatásuk a megfelelő fényvédelmi módszerek alkalmazására és a havonkénti rendszeres önvizsgálatra [17,22,28,29]. Az egyéni rizikófaktoroktól függően a transzplantált betegek 3, 6, 12 havonkénti bőrgyógyászati vizsgála-ta lenne indokolt [25,29].…”

Section: Megbeszélésunclassified

Nonmelanoma bőrtumorok kezelési lehetőségei szervtranszplantált betegeknél egy esetismertetés kapcsán

et al. 2016

View full text Add to dashboard Cite

A szerzők egy 59 éves férfi esetét mutatják be, akinél először 1983-ban, majd 2000-ben végeztek vesetranszplantáci-ót. Az első veseátültetést követően két évvel jelent meg az első laphámsejtes carcinoma a bőrön, majd 2003-tól évente legalább kettő praecancerosus laesio vagy nonmelanoma bőrdaganat sebészeti eltávolítása történt. Ezek a tumorok elsősorban a napfénynek kitett bőrterületeken jelentek meg, multiplexen. Tekintettel arra, hogy agresszív viselkedésűek lehetnek és recidívára hajlamosak, komplex kezelést alkalmaztak a betegnél, amely magába foglalta az immunszuppresszió során alkalmazott gyógyszerek megváltoztatását, illetve mezőterápiák alkalmazását. Az eset bemutatása kapcsán a szerzők áttekintik ezeket a kezelési lehetőségeket, hangsúlyozva, hogy nemcsak a bőrdaganatok minél korábbi felismerése és aktív kezelése szükséges, hanem a betegek megfelelő fényvédelemre való oktatása és bőrgyógyászati gondozása is a bőrtumorok kialakulásának megelőzése érdekében. Orv. Hetil., 2016, 157(24), 971-976.Kulcsszavak: veseátültetés, nonmelanoma bőrdaganat, immunszuppresszív terápia, mezőkarcinogenezis, mezőterá-pia, fotodinámiás terápia Treatment options of non-melanoma skin tumors in organ transplant recipients in relation to a case reportThe authors present the case of a 59-year-old male patient, whose first kidney transplantation was in 1983 and the second in 2000. The first squamous cell carcinoma appeared on the skin 2 years after the first transplantation. Since 2003, at least two precancerous lesions or non-melanoma skin tumors have been removed surgically yearly. These cancers appeared predominantly on the sun-exposed skin, and were multiple. As these tumors could behave aggressively and prone to recurrence, complex treatment was applied, which included a switch in immunosuppressive drugs and the application of field therapies. The authors give an overview of these treatment options in relation to the case presentation, emphasizing that not only early detection and active treatment of the precancerous lesions and skin cancers are essential, but education of proper sun-protection methods and dermatology care are also important in order to avoid the development of these tumors.

show abstract

“…In the literature, the primary barriers to skin cancer screening include access to dermatology, insurance coverage, and a perceived lack of medical evidence for screening . The most significant barrier to skin cancer screening for SOTR reported was the perceived lack of medical evidence for skin cancer screening among transplant providers.…”

Section: Introductionmentioning

confidence: 99%

Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines

et al. 2019

Self Cite

View full text Add to dashboard Cite

Skin cancer is the most common malignancy affecting solid organ transplant recipients (SOTR), and SOTR experience increased skin cancerassociated morbidity and mortality. There are no formal multidisciplinary guidelines for skin cancer screening after transplant, and current practices are widely variable. We conducted three rounds of Delphi method surveys with a panel of 84 U.S. dermatologists and transplant physicians to establish skin cancer screening recommendations for SOTR. The transplant team should risk stratify SOTR for screening, and dermatologists should perform skin cancer screening by full-body skin examination. SOTR with a history of skin cancer should continue regular follow-up with dermatology for skin cancer surveillance. High-risk transplant patients include thoracic organ recipients, SOTR age 50 and above, and male SOTR. High-risk Caucasian patients should be screened within 2 years after transplant, all Caucasian, Asian, Hispanic, and high-risk African American patients should be screened within 5 years after transplant. No consensus was reached regarding screening for low-risk African American SOTR. We propose a standardized approach to skin cancer screening in SOTR based on multidisciplinary expert consensus. These guidelines prioritize and emphasize the need for screening for SOTR at greatest risk for skin cancer. ª 2019 Steunstichting ESOT

show abstract

Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations

Abstract: The dermatologic evidence for regular skin cancer screening in transplant patients needs dissemination to our transplant colleagues. This is a significant practice gap which can be appropriately closed by integrating dermatologists into the transplant team.

Cited by 19 publications

References 79 publications

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

Nonmelanoma bőrtumorok kezelési lehetőségei szervtranszplantált betegeknél egy esetismertetés kapcsán

Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines

Contact Info

Product

Resources

About